Article (Scientific journals)
Pharmacologic treatment of obesity, food intake, and reversal of metabolic disorders.
SCHEEN, André; PAQUOT, Nicolas
2007In Current Research in Nutrition & Food intake, 3, p. 123-133
Peer reviewed
 

Files


Full Text
obesity treatment0001.pdf
Author preprint (4.84 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Orlistat; CB1 receptors; cholesterol levels; Sibutramine; Weight loss
Abstract :
[en] The present paper is reviewing the current place of weight-reducing drugs in the overall management of overweight/obese subjects, especially those with metabolic disorders and type 2 diabetes. Anti-obesity agents should be carefully evaluated in long-term (1-2 years) randomized controlled trials. Recent systematic reviews and meta-analysis assessed both the safety and efficacy of the two drugs currently used in the treatment of obesity, i.e. orlistat, a gastric and pancreatic lipase inhibitor that reduces fat absorption from the gut, and sibutramine, a combined norepinephrine and serotonin reuptake inhibitor that regulates food intake. Rimonabant, a new compound acting as selective blocker of CB1 receptors of the endocannabinoid system, raises much interest as it promotes weight reduction by a central effect and also exerts peripheral effects targeting cardiometabolic risk. Special attention will be paid to beneficial metabolic effects resulting from (even moderate) weight loss and to possible additional effects beyond weight reduction.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
PAQUOT, Nicolas ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Pharmacologic treatment of obesity, food intake, and reversal of metabolic disorders.
Publication date :
2007
Journal title :
Current Research in Nutrition & Food intake
Volume :
3
Pages :
123-133
Peer reviewed :
Peer reviewed
Available on ORBi :
since 25 October 2011

Statistics


Number of views
22 (1 by ULiège)
Number of downloads
208 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi